Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer

Clinical Prostate Cancer

Volumn 3, Issue 2, 2004, Pages 77-79

  Price, Nancy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE METASTASIS; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FATIGUE; FEVER; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; MALE; MYALGIA; PROSTATE CANCER; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 6344278505     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1540-0352(11)70065-8     Document Type: Article

References (13)

1. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88:2989-2994.
2. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68:74-80.
3. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19:3562-3571.
4. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synmase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235-242.
5. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004; 94:164-170.
6. Ullen A, Lennartsson L, Hjelm-Eriksson M, et al. Additive/synergistic anti-tumoral effects on prostate cancer cells in vitro following treatment with a combination of gemcitabine and zoledronic acid. Proc Am Soc Clin Oncol 2003; 22:432 (Abstract #1737).
7. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150-3157.
8. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91:1191-1200.
9. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of Zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
10. Tchekmedyian S, Rosen LS, Gordon D, et al. Long-term efficacy and safety of Zoledronic acid in reducing skeletal complications in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol 2003; 22:630 (Abstract #2532).
11. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882.
12. Saad F, Gleason DM, Murray R, et al. Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer. Proc Am Soc Clin Oncol 2004; 23:399 (Abstract #4575).
13. Chin JL, Saad F, Gleason DM, et al. Clinical benefit of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer based on history of skeletal complications. Proc Am Soc Clin Oncol 2004; 23:399 (Abstract #4576).